OptiBiotix Health PLC Equity Research & Stock Reports

Equity Research, Broker Reports, and media content on OptiBiotix Health PLC

Access the latest forecasts, broker valuations, multiples, and video content from the city about OptiBiotix Health PLC
See live updates from analysts, company announcements, and other news in a personalised/single dashboard

15 Jan 24

Hybridan Small Cap Feast - 15 Jan 24

15th January 2024 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment obje

Companies: OHG Z29 FTC IOF UJO RFX OPTI HERC BOOM

Hybridan

22 Nov 23

Hybridan Small Cap Feast - 22 Nov 23

22nd November 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment obj

Companies: DRE CTL PEB QED PEG TENG OPTI DUKE AURR

Hybridan

02 Nov 22

Cenkos: OptiBiotix Health Plc -- Momentum Building

OptiBiotix has opened an online store on Tmall, a cross-border online marketplace through which OptiBiotix has launched a range of GoFigure shakes direct to Chinese consumers. OptiBiotix has partnered with a Tmall agency, InReady, to promote and operate its Tmall store. Momentum has been building at OptiBiotix in recent months, with the company launching GoFigure products in the sizeable Indian and Chinese markets, as well as receiving approval for a third: Saudi Arabia. We believe these new pro

Companies: OptiBiotix Health PLC

Cavendish

28 Sep 22

Cenkos: OptiBiotix Health Plc -- Interim Results

OptiBiotix has issued its interim results for the six months ended 30 June 2022. In line with the company's August trading update, revenues have fallen to £0.12m as delays to customer restocking and new product launches impacted the top-line. Whilst the operating loss grew to £1.11m, as the company invested in key management personnel, OptiBiotix delivered over £10.2m in value to shareholders through a dividend in specie following the listing of ProBiotix Health (PBX) in March 2022. Post-period,

Companies: OptiBiotix Health PLC

Cavendish

21 Sep 22

Cenkos: OptiBiotix Health Plc -- GoFigure Launch with Apollo

OptiBiotix has launched its GoFigure weight management range in India through its commercial partner Apollo Hospitals (Apollo). Apollo owns and operates the largest pharmacy network across India and will initially stock the GoFigure range in key stores in major Indian cities, as well as online. Apollo is one of three large partners which entered commercial agreements with OptiBiotix in late-2021. The launch demonstrates OptiBiotix' strategic shift towards selling a greater proportion of finished

Companies: OptiBiotix Health PLC

Cavendish

24 Aug 22

Cenkos: OptiBiotix Health Plc - Trading update

OptiBiotix has issued a trading update ahead of the group's half year results for the six months ended 30 June 2022. Results will be affected by the new accounting treatment of recently spun-out ProBiotix Health (PBX), as well as the timing of several larger customer orders. As such, OptiBiotix expects total revenues of c£120k for the period, resulting in revenues being materially behind market expectations. OptiBiotix expects to return to growth by 2023; however, given the ongoing uncertainty a

Companies: OptiBiotix Health PLC

Cavendish

21 Jul 22

Cenkos: OptiBiotix Health Plc -- Commercial and Scientific Update

OptiBiotix has issued a commercial and scientific update, highlighting the significant progress made across its range of prebiotic ingredients and products. The update further demonstrates OptiBiotix' ability to grow its product range, expand applications for existing products and extend its reach into new territories. OptiBiotix, is also conducting further clinical work to increase the body of evidence supporting its products to help drive future growth. We maintain our Buy rating.

Companies: OptiBiotix Health PLC

Cavendish

28 Jun 22

Cenkos: OptiBiotix Health Plc -- Final results

OptiBiotix has reported final results for the year to December 2021, with revenues growing 45% to £2.2m and the EBITDA loss increasing to £1.0m, reflecting the increased investment in the business. Post-period end, OptiBiotix has continued to return value to shareholders through the successful spin-out and listing of its ProBiotix Health division. Future growth of the company is supported by commercial agreements with large partners and a substantial pipeline of opportunities through its 2nd gen

Companies: OptiBiotix Health PLC

Cavendish

01 Jun 22

Cenkos: OptiBiotix Health Plc -- ProBiotix probiotic yoghurt launch

ProBiotix, OptiBiotix' former subsidiary in which it holds a 44% shareholding, has announced the launch of a probiotic functional yoghurt brand containing the proprietary cholesterol reducing functional ingredient LPLDL. We see this as a significant milestone for ProBiotix, having overcome several technical hurdles during the 2.5-year development process, extending the use of LPLDL into functional dairy foods and offering the potential to replicate the development in other geographies and functi

Companies: OptiBiotix Health PLC

Cavendish

20 May 22

Cenkos: Healthcare Sector - Ward Round

Weekly round-up of AIM-listed healthcare news. Venture Life Group, GENinCode, Kromek, Alliance Pharma, Polarean Imaging, Benchmark Holdings, Ondine Biomedical, Verici Dx, Faron Pharmaceuticals, Avacta Group, Abingdon Health, Open Orphan, Belluscura, Hutchmed (China), Oxford Biodynamics

Companies: GENI RUA SBTX VLG IXI IUG HEIQ OPTI IHC CREO ANIC

Cavendish

13 May 22

Cenkos: Healthcare Sector -- Ward Round

Weekly round-up of AIM-listed healthcare news. Agronomics, Eden Research, IXICO, HeiQ, Trellus Health, NetScientific, Circassia, 4basebio, Fusion Antibodies, Surgical Innovations Group, Yourgene Health, Abingdon Health, Verici Dx, Poolbeg Pharma, Omega Diagnostics

Companies: GENI RUA SBTX VLG IXI IUG HEIQ OPTI IHC CREO ANIC

Cavendish

06 May 22

Cenkos: Healthcare Sector -- Ward Round

Weekly round-up of AIM-listed healthcare news. Intelligent Ultrasound, Inspiration Healthcare, Agronomics, CareTech Holdings, e-therapeutics, ABCAM, EKF Diagnostics, HUTCHMED (China), Benchmark Holdings, Totally, ImmuPharma, Open Orphan, Destiny Pharma, Polarean Imaging, Induction Healthcare.

Companies: GENI RUA SBTX VLG IXI IUG HEIQ OPTI IHC CREO ANIC

Cavendish

29 Apr 22

Cenkos: Healthcare Sector -- Ward Round

IXICO, HeiQ, Creo Medical, GlaxoSmithKline, Totally, Advanced Oncotherapy, Arecor Therapeutics, Midatech Pharma, Futura Medical, Yourgene Health, Renalytix, Polarean Imaging, Diurnal, Novacyt, Faron Pharmaceuticals, Poolbeg Pharma, ANGLE

Companies: GENI RUA SBTX VLG IXI IUG HEIQ OPTI IHC CREO ANIC

Cavendish

30 Mar 22

Cenkos: OptiBiotix Health Plc -- Trading update and listing

OptiBiotix recently announced a trading update for the 12-months to Dec-21 and its intention to list its ProBiotix Health division. The company expects revenues of £2.2m, in-line with our forecast, while operational investment suggests a group level EBITDA loss of c£0.9m, driven by one off recruitment and consultancy costs, versus our previous £0.3m loss forecast. Both divisions saw revenue and EBITDA (pre-central costs) growth during the year, building on the 2020 progress. Supporting future gr

Companies: OptiBiotix Health PLC

Cavendish

11 Feb 22

OptiBiotix Health's plans for the next generation of pre’ and probiotics